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ABSTRACT
Altritol-modified nucleic acids (ANAs) support
RNA-like A-form structures when included in
oligonucleotide duplexes. Thus altritol residues
seem suitable as candidates for the chemical
modification of siRNAs. Here we report that ANA-
modified siRNAs targeting the MDR1 gene can
exhibit improved efficacy as compared to unmodi-
fied controls. This was particularly true of ANA
modifications at or near the 30 end of the sense or
antisense strands, while modification at the 50 end
of the antisense strand resulted in complete loss of
activity. Multiple ANA modifications within the
sense strand were also well tolerated. Duplexes
with ANA modifications at appropriate positions in
both strands were generally more effective than
duplexes with one modified and one unmodified
strand. Initial evidence suggests that the loss
of activity associated with ANA modification of the
50-antisense strand may be due to reduced phos-
phorylation at this site by cellular kinases. Treat-
ment of drug resistant cells with MDR1-targeted
siRNAs resulted in reduction of P-glycoprotein (Pgp)
expression, parallel reduction in MDR1 message
levels, increased accumulation of the Pgp substrate
rhodamine 123, and reduced resistance to anti-
tumor drugs. Interestingly, the duration of action of
some of the ANA-modified siRNAs was substantially
greater than that of unmodified controls. These
observations suggest that altritol modifications may
be helpful in developing siRNAs with enhanced
pharmacological effectiveness.
INTRODUCTION
There has recently been substantial interest in potential
therapeutic exploitation of gene regulation based on
RNA interference (RNAi). The endogenous regulatory
mechanisms involved in the physiological role of RNAi
(1) can be activated via the delivery of short double-
stranded RNAs (siRNA) to the cell interior (2). The
mechanism of targeted mRNA degradation by siRNA is
highly complex and not fully understood. It involves the
formation of an RNA-induced silencing complex (RISC)
that contains the argonaute 2 protein, while the dicer
RNase and other proteins may also be important in
loading of siRNA on to the RISC complex (3). In order
to exploit RNAi therapeutically in mammals it will be
important to develop siRNAs that are speciﬁc, potent,
eﬃcacious and persistent in their action. Enhancing the
delivery of siRNA in the in vivo setting will also be a key
problem. Many of these issues are being addressed
through various chemical modiﬁcation approaches.
A variety of strategies for siRNA modiﬁcation have
been pursued including alterations in the backbone
chemistry, 20-sugar modiﬁcations, nucleobase modiﬁca-
tions and others, as recently reviewed (4,5). These eﬀorts
have, in some cases, resulted in signiﬁcant improvements
in the biological eﬀectiveness of siRNA and have provided
important insights into how chemical modiﬁcation aﬀects
function. In terms of overall design, understanding of the
biochemical mechanism of RNA interference has provided
important guidelines; ﬁrst, the siRNA must maintain an
A-form (RNA-like) duplex, second, the 50-position on the
antisense strand must be able to be phosphorylated, third,
to be eﬀective siRNAs should have low thermodynamic
stability in the 50 antisense region (1,5,6). These general
design principles can then be further evolved through the
use of selected chemical modiﬁcations.
Sulfurization of the backbone to form phosphorothio-
ate oligonucleotides (PS) has been a popular modiﬁcation
for both antisense and siRNA. The PS modiﬁcation
enhances nuclease stability but at the cost of reduced
melting temperature and increased non-speciﬁc binding
to proteins (7). In general, PS modiﬁcations of siRNA are
well-tolerated although some reports indicate increased
toxicity and reduced eﬃcacy (8,9). Boranophosphates are
another interesting backbone modiﬁcation that have been
reported to be compatible with high siRNA activity (10).
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well tolerated. Compounds with 20 ﬂuoro modiﬁcations
have increased thermodynamic stability and increased
resistance to nucleases; several reports indicate that
extensive modiﬁcation of this type in either sense or
antisense strand seems compatible with retention of
siRNA activity (4). The 20-O-Me modiﬁcation is also
consistent with retention of an A-form helix; however the
impact of this substitution is somewhat controversial with
some reports indicating substantial reduction in siRNA
activity with extensive (but not limited) substitution, in a
position speciﬁc manner (9,11). On the other hand, one
report indicates that extensive 20-O-Me modiﬁcation
can be made in the sense strand without any loss of
activity (12). Bicyclic-locked nucleic acids (LNAs) that
confer high binding aﬃnity can be introduced selectively,
particularly when the central region of the siRNA duplex
is avoided (13). Relatively few nucleobase modiﬁcations
have been studied thoroughly for eﬀects on siRNA
activity (4). An interesting recent example is ribo-
ﬂuorotoluyl nucleotides that display increases in nuclease
stability along with maintained siRNA eﬀects (14).
Thus a variety of chemical modiﬁcations are consistent
with maintenance of siRNA activity; however, there
are few examples of substantial improvement in
the eﬃcacy of RNA interference through such
modiﬁcations.
Most of the modiﬁcations described above were
originally developed for use with antisense deoxy-
oligonucleotides; it seems worthwhile then to also
examine chemical modiﬁcations that are particularly
suited to RNA-type oligonucleotides. One such mod-
iﬁcation is the use of the 6-carbon sugar, altritol, in
place of the usual pentose ring. D-altritol oligonucleo-
tides (ANA) have been synthesized as mimics of RNA
with a conformationally rigid sugar moiety (15–17). The
main diﬀerence with most rigid conformation RNA
mimics is that a free hydroxyl group is present at the
carbon atom adjacent to the base moiety. ANA is able
to form very stable duplexes with RNA in a sequence-
speciﬁc manner, due to its pre-organization in a A-type
helix conformation (18). ANA is stable against enzy-
matic degradation in serum and has been shown to be
an excellent template for non-enzymatic synthesis of
complementary RNA’s (19). Although the structural
properties of ANA have been described, ANAs have not
been evaluated in a biological system as RNA mimic
until now.
MDR1, the gene chosen as the target for this study,
codes for the P-glycoprotein, a transmembrane ATPase
that serves as an eﬄux pump for a wide range of drug
molecules. MDR1 is often over-expressed in tumor
cells thus contributing to the multi-drug resistant
phenotype commonly seen in cancer (20). The fact that
MDR1 mRNA and P-glycoprotein are highly expressed
in multi-drug resistant cells, while P-glycoprotein has
a long turnover time, makes this target very refractory to
inhibition with antisense or siRNA oligonucleotides (21).
Thus we have evaluated ANA siRNAs in the context
of a challenging test system.
MATERIAL AND METHODS
The synthesis of the ANA oligonucleotides has been
described previously (16). The techniques used to evaluate
the impact of siRNAs on MDR1 expression and function
have been fully described in our previous publications
(21–23); a brief recapitulation is given below.
Treatment ofcells with siRNA oligonucleotides
Multi-drug-resistant NIH 3T3-MDR cells were cultured
as described (21). Hybridization of the siRNA strands was
done in Dharmacon universal buﬀer by heating the
solutions to 908C in a Perkin Elmer PCR machine, then
gradually cooling to 308C for 30min. Complexation of
siRNA with the cationic lipid lipofectamine 2000
(Invitrogen) was done according to the manufacturer’s
standard procedure. The oligonucleotides bound to
lipofectamine 2000 were mixed in 10% FBS/DMEM-H
and incubated with cells at 378C for 4h; media was then
removed and replaced with 2% FBS/DMEM-H and the
cells incubated for an additional 68–72h. Most of the
experiments were done with an MDR1 siRNA sequence
termed ORF1 (antisense sequence 30-dTdTCAUAACU
GUCGAUAAGCUU-50) while a limited number of
experiments were done with a second sequence termed
ORF2 that targets a distinct region on the MDR1 mRNA
(antisense sequence 30-dTdT CUUGAGAAUCGCAUA
CGUU-50).
Cytotoxicity
NIH 3T3-MDR cells were treated with lipofectamine
2000 complexes of standard or ANA-modiﬁed siRNA
oligos as described above. The cells were then replated
onto new 12-well plates and incubated overnight followed
by the addition of various concentrations of doxorubicin
for 24h. Evaluation of drug-induced cytotoxicity was
performed as described by monitoring changes in cell
number (22).
Immunostaining of P-glycoprotein
The level of cell surface expression of P-glycoprotein (Pgp)
was quantitated byimmunostaining usingaﬂow cytometry
assay. After treating NIH 3T3-MDR cells with standard or
ANA-modiﬁed siRNA complexes as described above, the
cells were washed with PBS, trypsinized, resuspended
in complete medium and washed again with PBS after
centrifugation. The levels of cell surface Pgp were
quantitated using 17F9R-Phycoerythrin conjugated
mouse anti human P-glycoprotein monoclonal antibody
(BD-Pharmingen) as described previously (22). Analysis
was done on a Becton Dickinson ﬂow cytometer using
Cicero software (Cytomation, Fort Collins, CO). Our
previous studies have shown that P-glycoprotein levels
are not aﬀected by non-targeted siRNAs.
Rhodamine123 accumulation
The ﬂuorophore rhodamine 123 is a substrate for the
P-glycoprotein eﬄux pump; thus rhodamine 123 accumu-
lation is often used as a surrogate for anti-tumor drug
uptake/retention (24). The accumulation of Rh123 by
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a ﬂow cytometry assay as described (22).
RNA extraction and real-time RT-PCR
Total RNA was isolated using a Tri Reagent kit
(Molecular Research Center, Inc.), and cDNA was
synthesized from total RNA using an oligo-dT primer.
Real-time PCR was performed using the ABI PRISM
7900 sequence detection system (Applied Biosystems,
Foster City, CA) as previously described (22). Primers
(Oligonucleotide Synthesis Core Facility, University of
North Carolina) and probes (Integrated DNA
Technologies, Santa Clara, CA) were designed using
Primer 4 software and were designed to span exon–
intron junctions. The MDR1 signal was normalized using
human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) by dividing the copies of MDR1 by the
copies of human GAPDH.
Nuclease stability
For nuclease stability experiments, unmodiﬁed or
ANA-modiﬁed siRNA duplexes were incubated with
partially puriﬁed nucleases or with calf serum.
Thereafter the material was analyzed on 3% agarose/
ethidium bromide gels in BPB/XC loading buﬀer, electro-
phoresed at 100V for 45min, and residual duplexes
imaged by ultraviolet illumination.
Thermaltransitions
Melting points (Tm) for conventional and modiﬁed ORF1
duplexes were measured using a Shimadszu thermal melt
apparatus.
RESULTS
Altritol nucleic acids (ANAs) are novel RNA analogs that
have a six membered D-altritol ring with a nucleobase at
the 2-(S)- position (Figure 1A). They can be considered as
hexitol nucleic acid (25) analogs that have an additional
hydroxy group at the 30 position. In duplex RNA the
hydroxy group is directed into the minor groove and
contributes to helix stability. A diagram of an
ANA nucleotide and of an ANA strand duplexed with
conventional RNA is shown in Figure 1B. A series of
ANA-modiﬁed oligonucleotides were synthesized with
modiﬁcations at various positions in the sense or antisense
strands. These are indicated in Table 1. The sequences
ORF1 and ORF2 target two distinct regions of the MDR1
open reading frame.
Screeningand dose–response relationships
ANA-modiﬁed strands of the ORF1 sequence were
complexed with conventional RNA to form siRNA
duplexes and screened for activity in NIH-3T3-MDR
cells by measuring the reduction in cell surface expression
of P-glycoprotein, the MDR1 gene product. As seen in
Figure 2, a wide range of eﬃcacy was observed.
Modiﬁcations at the 50 end of the antisense strand
abolished activity, while extensive modiﬁcation within
the central region of the antisense strand also lowered
activity. By contrast, modiﬁcations at the 30 end of either
the sense or antisense strand resulted in eﬃcacies that were
substantially greater than that of unmodiﬁed siRNA (for
example, oligonucleotides 2392, 2193). Multiple modiﬁca-
tions within the sense strand were also tolerated with only
modest reductions in siRNA eﬀectiveness
(e.g. oligonucleotides 2312, 2313). The activity of the
various modiﬁed oligonucleotides was not correlated in
any way with their thermal stability; for example, multiply
modiﬁed oligonucleotide 2365 had the highest Tm when
complexed with unmodiﬁed RNA (738C versus 678C
for conventional ORF1 siRNA) but had little activity
(Tm data not shown).
We also examined the eﬀects of ANA-modiﬁed siRNAs
targeted to a distinct region of the MDR1 mRNA. These
siRNAs, termed ORF2 ANA sequences, also displayed
enhanced activity as compared to conventional siRNA
targeting the ORF2 sequence (Table 2). Thus the
beneﬁcial eﬀects of ANA modiﬁcation are not limited to
a particular sequence within the MDR1 message. As with
the ORF1 sequences, modiﬁcations at the 50 end of the
antisense strand for ORF2 were not well tolerated.
Figure 1. The chemistry and structure of altritol-modiﬁed oligonucleo-
tides. (A) The chemical structure of ANA oligonucleotides. (B) Model
of an ANA–RNA duplex; the green strand represents the
ANA–modiﬁed oligonucleotide.
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provided additional advantages in terms of eﬀectiveness
(Figure 3A). For example, the modiﬁed sense strand 2359
and the modiﬁed antisense strand 2470 were both eﬀective
when duplexed with an unmodiﬁed partner; however, the
2359/2470 duplex was even more eﬀective. Interestingly,
duplexing a poorly eﬀective antisense strand with an
eﬀective sense strand often partially ‘rescued’ siRNA
activity; this can be seen in the 2359/2362 duplex in
Figure 3A, suggesting that the overall characteristics
of the duplex are important in RISC loading and
mRNA degrading activity.
In control experiments, we conﬁrmed that variants of
active ANA-modiﬁed oligonucleotides that have several
mismatches in their sequences are completely inactive
(Figure 3B); this is similar to the situation for conven-
tional siRNAs targeting MDR1, as we have previously
shown (21).
Some of the more promising duplexes with modiﬁ-
cations in one or both strands were tested for
inhibition of P-glycoprotein expression over a range of
siRNA concentrations. As seen in Figure 4, the enhanced
activities of the ANA-modiﬁed versions were present over
the entire concentration range. The proﬁles indicate both
increased potency with eﬀects at lower concentration and
increased eﬃcacy with greater responses at the plateau.
Roleof 50 Phosphorylation
Antisense strands with ANA modiﬁcations at the 50
position were completely inactive, but the reason for this
was not immediately apparent. There is a stabilizing eﬀect
of the ANA residue, thus potentially undermining the
requirement for local instability at the 50 antisense position
(6); however, the same stabilizing eﬀect would occur with
modiﬁcations near the 30 end of the sense strand, but these
are well tolerated. Another possibility is that the 50 ANA
residue interferes with the required 50 phosphorylation of
the antisense strand of siRNA by endogenous kinases (5).
To examine this possibility, we synthesized a version of an
inactive oligonucleotide (2361) that has a 50 phosphate
group (termed 2516-P). As seen in Figure 5, the presence
Table 1. ANA(*)-modiﬁed RNAs that were used in the siRNA experiment. (Note: ORF1 and ORF2 refer to two distinct target regions of the
MDR1 mRNA)
ORF1
Sense strand (50 !30)
2191 GUA* UUG A*CA GCU AUU CGA AdTdT
2192 GUA UUG ACA GCU AUU CGA* AdTdT
2307 GUA UUG ACA GCU AUU* CGA AdTdT
2308 GUA UUG ACA GCU* AUU CGA AdTdT
2309 GUA UU*G ACA GCU AUU CGA AdTdT
2310 GU*A UUG ACA GCU AUU CGA AdTdT
2311 GUA UU*G ACA GCU* AU*U* CGA AdTdT
2312 GUA* UU*G ACA* GCU* AUU* CGA* AdTdT
2313 GU*A* U*U*G A*CA* GCU* A*U*U* CGA* A*dTdT
2357 GUA UU*G ACA* GC*U AU*U CG*A AdTdT
2358 G*U*A UUG ACA GCU AUU CGA* A*dTdT
2359 GUA UUG ACA* G*C*U AUU CGA AdTdT
2385 GUA UUG ACA GCU AUU CGA* A*dTdT
2360 GUA U*U*G* A*C*A* G*C*U* A*U*U* C* CA AdTdT
2471 G*UA UUG ACA GCU AUU CGA AdTdT
2472 G*U*A UUG ACA GCU AUU CGA AdTdT
Antisense strand (50 !30)
2193 UUC GAA UAG CUG UCA AUA* CdTdT
2194 UUC GAA UAG CUG UCA A*UA CdTdT
2314 UUC GAA UAG CUG UCA AU*A CdTdT
2315 UUC GAA UAG CUG U*CA AUA CdTdT
2316 UUC GAA UAG CU*G UCA AUA CdTdT
2317 UUC GAA U*AG CUG UCA AUA CdTdT
2318 UU*C GAA UAG CUG UCA AUA CdTdT
2361 U*U*C GAA UAG CUG UCA AUA CdTdT
2362 UUC GAA UAG* C*U*G UCA AUA CdTdT
2363 U*U*C GAA UAG CUG UCA AUA* C*dTdT
2364 UUC GA*A UA*G CU*G UC*A AU*A CdTdT
2365 UUC G*A*A* U*A*G* C*U*G* U*C*A* A*UA* CdTdT
2469 UUC GAA UAG CUG UCA AUA C*dTdT
2470 UUC GAA UAG CUG UCA AUA* C*dTdT
ORF2
Sense strand (50 !30)
2485 GAA CUC UUA GCG UAU GCA* A*dTdT
2486 G*A*A CUC UUA GCG UAU GCA* A*dTdT
Antisense strand (50 !30)
2487 UUG CAU ACG CUA AGA GUU* C*dTdT
2488 U*U*G CAU ACG CUA AGA GUU CdTdT
Nucleic Acids Research, 2007, Vol. 35, No. 4 1067of a 50-phosphate group partially rescues the eﬀectiveness
of the ANA-modiﬁed antisense strand. Oligonucleotides
2361 and 2516-P have exactly the same ANA modiﬁcation
at the 50 position, but 2516-P was phosphorylated during
synthesis. The observed ‘rescue’ of the ‘knockdown’ eﬀect
is not large but it is consistently observed. The degree of
rescue was not aﬀected by the presence or absence of
serum during the transfection process (data not shown),
suggesting that the relatively modest rescue is not because
of the possible dephosphorylation of 2516-P by serum
phosphatases, but rather that dephosphorylation and
inactivation of 2516-P may take place within the cell.
Interestingly, when we extended the period of transfec-
tion beyond the 4h usually used, the eﬀect of the
50 phosphorylated ANA antisense was much greater,
while the unphosphorylated ANA antisense remained
inactive (Figure 5 inset). This suggests that maintaining
a persistent external pool of 50 phosphorylated siRNA,
and thus continuous delivery, may allow adequate loading
of the RISC complex even in the face of rapid dephos-
phorylation by cellular phosphatases.
RT-PCR and functional correlates
We examined whether the observed siRNA-mediated
reductions in P-glycoprotein expression were accompanied
by similar changes at the message level and by functional
changes in drug transport. As seen in Figure 6, reductions
MDR1 mRNA were observed that paralleled reduced
expression of the protein product, suggesting that the
action of the ANA-modiﬁed siRNAs is at the level of
message degradation.
The observed reductions in P-glycoprotein levels
were also accompanied by increases in the intracellular
accumulation of P-glycoprotein substrates. Thus
Figure 7A illustrates the eﬀect of conventional or ANA-
modiﬁed siRNAs on cell levels of the lipophilic dye
Rh123. Notably a duplex with modiﬁcations in both
strands (2470/2358) was signiﬁcantly more eﬀective than
either modiﬁed strand complexed with unmodiﬁed RNA,
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Figure 2. Screening of ANA-modiﬁed siRNAs for activity versus MDR1. NIH 3T3-MDR cells were treated with 50 nM ORF1 sequence siRNA
complexed to lipofectamine 2000 for 4h at 378C in complete medium. Thereafter the cells were placed in fresh medium (2% FBS/DMEM-H) and
cultured for an additional 72h. Cell surface P-glycoprotein levels were quantitated by immunostaining and ﬂow cytometery as described in methods.
Results are expressed as the percentage reduction in Pgp expression compared to untreated control cells. The positions of the ANA modiﬁcations are
indicated in the ﬁgure. Results are means of three determinations. Figure 2 inset: a typical ﬂow cytometry analysis is shown comparing Pgp levels in
untreated control cells with cells treated with ANA-modiﬁed or control (unmodiﬁed) siRNAs. In this and subsequent ﬁgures unmodiﬁed anti-MDR1
siRNA is designated simply as ‘siRNA’ or ‘siRNA control’.
Table 2. Eﬀects of ORF2 siRNAs on P-glycoprotein expression (means
and standard errors of 6 determinations)
Oligonucleotide Percentage reduction in P-glycoprotein
siRNA control 30.7þ/ 6.3
2485/2487 50.8þ/ 4.1
2485/2488 4.1þ/ 1.4
2511/2487 47.8þ/ 5.9
2511/2488 2.9þ/ 1.6
1068 Nucleic Acids Research, 2007, Vol. 35, No. 4which in turn were superior to conventional siRNA.
A strand that was inactive in terms of P-glycoprotein
reduction (2361) was also inactive in this assay.
The changes in Rh123 accumulation were closely paral-
leled by changes in cell surface P-glycoprotein expression
in the same experiment, as indicated in the inset in
Figure 7A. Treatments with conventional or modiﬁed
siRNA also resulted in changes in cellular response to
cytotoxic drugs. Thus as seen in Figure 7B, the dose versus
toxicity curve for the anti-tumor drug doxorubicin
was left-shifted by treatment of NIH-3T3-MDR cells
with siRNAs that reduced P-glycoprotein expression.
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Figure 3. (A) Eﬀects of ANA modiﬁcations in both strands of the duplex. NIH 3T3-MDR cells were treated with 50 nM siRNA and monitored for
Pgp expression by immunostaining and ﬂow cytometry as in Figure 2. A comparison is shown between siRNAs with ANA modiﬁcations in one
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siRNAs with ANA modiﬁcations in both strands (hatched bars). Results are the means of triplicate determinations. (B) Eﬀects of mismatches. ANA-
modiﬁed ORF2 siRNAs (50 nM) with (2531/2532) or without (2485/2487) 4 mismatches to the target sequence were tested for inhibition of Pgp
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Nucleic Acids Research, 2007, Vol. 35, No. 4 1069Once again the most robust eﬀects were attained with
duplexes having ANA modiﬁcations in both strands.
The maximal observed change in doxorubicin ID50 was
slightly more than 2-fold, consistent with the 50–75%
reductions in P-glycoprotein expression observed.
Persistence ofeffects
An important aspect of siRNA pharmacology is to attain
persistent ‘knockdown’ of the target. Many factors will
contribute to this, including the overall stability of the
siRNA to nucleases, cellular uptake and import processes,
and biochemical interactions with the RISC complex.
We compared the duration of P-glycoprotein reduction in
cells treated with conventional and ANA-modiﬁed
siRNAs. As shown in Figure 8A, with conventional
ORF1 siRNA almost all of the ‘knockdown’ eﬀect seen at
4 days post-siRNA treatment was lost by day 6 as mRNA
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for Pgp expression by immunostaining and ﬂow cytometry as in
Figure 2. Ordinate: percentage reduction in Pgp expression versus
untreated control cells. Abscissa: concentration of siRNA (nM).
Results are the means of triplicate determinations.
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Figure 5. Rescue of siRNA eﬀectiveness by 50 phosphorylation.
Antisense oligonucleotide 2361 which has ANA modiﬁcations at its
50end (and is therefore inactive) was synthesized including a 50-terminal
phosphate group and now termed 2516-P. NIH 3T3 MDR cells were
treated with 50 nM siRNAs for 4h, washed, and then analyzed for Pgp
expression after 72h. Results are expressed as the percentage reduction
in Pgp expression compared to untreated control cells (means and
standard errors of 3 determinations). (Inset) Assays after long
exposures. The analysis was exactly the same as above except that
the siRNAs and transfection agent were left in contact with the cells for
the entire 76-h period.
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cellular mRNA levels were analyzed by RT-PCR as described in methods. Ordinate: fraction of MDR1 mRNA as compared to untreated control
cells. Results are means of three determinations.
1070 Nucleic Acids Research, 2007, Vol. 35, No. 4and protein levels returned to normal. By contrast, using
ORF1 sequence siRNAs with ANA modiﬁcations in
a single strand, 50% of the day 4 eﬀect was maintained
to day 6, while with modiﬁcations in both strands
essentially all of the ‘knockdown’ persisted to day 6 and
substantial eﬀects were still present at day 8. A similar but
slightly more modest eﬀect on duration of action was seen
with ANA-modiﬁed ORF2 oligonucleotides (Figure 8B).
This remarkable enhancement of persistence of action
may be an important pharmacological advantage for
ANA siRNAs. While many factors can contribute to
persistent biological eﬀects of siRNA, one of them may
well be nuclease stability. Thus we tested the stability
of conventional and ANA-modiﬁed siRNAs to nucleases
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Figure 7. (A) Eﬀects of siRNAs on Rh123 accumulation. NIH 3T3-MDR cells were treated with 50 nM ANA-modiﬁed or conventional siRNAs as
in Figure 2. After 72h the cells were exposed to 1mg/ml rhodamine 123 for 1h. The cells were washed, harvested and analyzed for Rh123 levels by
ﬂow cytometry, as described in methods. Results are normalized based on a value of 1 for untreated cells. The data represents means and standard
errors for three determinations. The inset in 7A illustrates cell surface Pgp levels in the cells used in one of the Rh123 experiments. (B) Eﬀects of
siRNAs on doxorubicin toxicity. NIH 3T3-MDR cells were treated with 50 nM ANA-modiﬁed or conventional siRNAs as in Figure 2. After 72h the
cells were exposed for 24h to various concentrations of doxorubicin. After a further 48h, cells were harvested and cell numbers were determined
using a particle counter as described in methods. Results are expressed as the percentage of the cell number in controls not treated with siRNA.
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Nucleic Acids Research, 2007, Vol. 35, No. 4 1071in an in vitro assay. However, as seen in Figure 9, when we
compared a standard siRNA to one of the more potent
ANA-modiﬁed siRNA duplexes (2385/2470), we did not
observe any signiﬁcant increase in stability to micrococcal
nuclease or to the nuclease activity in serum. Thus, factors
other than nuclease stability may contribute to the long
duration of the ANA siRNA eﬀects, although we cannot
as yet rule out the possibility that ANA modiﬁcation may
increase stability to endogenous cellular nucleases.
DISCUSSION
Based on the results reported here it seems that
ANA-modiﬁed oligonucleotides have some desirable
features for use as siRNAs including increased eﬃcacy
and prolonged duration of action. The eﬀects of ANA
modiﬁcations were screened via quantiﬁcation of the
reduction in expression of P-glycoprotein and were further
examined at the mRNA level and via functional assays.
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Figure 8. Persistent eﬀects of ANA-modiﬁed siRNAs. (A) Control and ANA-modiﬁed ORF1 oligonucleotides. NIH 3T3-MDR cells were treated
with 50 nM ANA-modiﬁed or conventional ORF1 siRNAs as in Figure 2. Cells were recovered on days 4–8 after siRNA treatment and monitored
for P-glycoprotein expression by immunostaining and ﬂow cytometry. The percentage reduction in Pgp expression on day 4 was taken as 1 and the
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strand were not tolerated; however, the reason for this is
not entirely clear. While there is a stabilizing eﬀect of the
ANA residue, thus opposing the requirement for local
thermodynamic instability at the 50 antisense position (6),
the same would be true of modiﬁcations near the 30 end of
the sense strand, but these are well tolerated. One likely
possibility is that the presence of an ANA modiﬁcation
hinders phosphorylation of the 50-OH by cellular
kinases. This is supported by our observations that a
50 ANA antisense strand synthesized with a 50 phosphate
moiety was more eﬀective than the equivalent
unphosphorylated strand. Chemical modiﬁcation of the
50 position of the antisense strand often results is loss of
activity (5); at least in the case of ANAs, reduced
susceptibility to phosphorylation seems to be an impor-
tant aspect of this phenomenon.
Excellent eﬀects were attained with ANA modiﬁcations
of the 30 regions of the sense or antisense strands with
eﬃcacies as much as 2-fold greater than conventional
siRNA. Once again the basis for this is uncertain, but it
does not seem to be due to increased stability to nucleases.
Although fully modiﬁed ANA oligonucleotides seem to be
more resistant to serum nucleases, this was not the case for
the partially modiﬁed compounds tested here. Extensive
modiﬁcation of the central region of the sense strand is
also compatible with maintenance of siRNA activity.
In some respects this is surprising based on the ﬁnding
that the sense strand usually is degraded as the RISC
complex becomes functional; however, an alternate path-
way that does not require sense strand degradation has
also been noted (26). Our observations are consistent
with other reports indicating that certain modiﬁcations
(e.g. 20-O-Me) are well tolerated on the sense strand (12).
As interesting aspect of our ﬁndings is that, in general,
use of ANA modiﬁcations in both strands increases
eﬀectiveness while increasing the number of ANA residues
on one strand does not. Thus the greatest improvements
in eﬃcacy were attained with duplexes having 30 ANA
modiﬁcations in both strands. The mechanistic basis of
this eﬀect is not yet understood.
The reductions in P-glycoprotein expression observed
subsequent to siRNA treatment were paralleled by
reduction in MDR1 mRNA levels and by changes in
drug accumulation and drug resistance. In general there
was good quantitative agreement among all of these
parameters, with certain siRNAs having ANA modiﬁca-
tions on both strands demonstrating the greatest activity
in each of these assays. It is interesting that the ANA
modiﬁcations often were not only compatible with
retention of siRNA activity, but in many cases led to
enhanced activity. Particularly noteworthy is the substan-
tially increased duration of action of some of the ANA-
modiﬁed siRNAs. This can be a signiﬁcant advantage for
therapeutic applications where persistent eﬀects may be
desirable. A recent publication has indicated that
20-deoxy-20-ﬂuoro-b-D-arabinonucleotide(FANA)-modiﬁed
siRNAs also displayed increased persistence of action,
an eﬀect that was attributed to nuclease stability (27).
The increased biological activity and persistence of
action of ANA-modiﬁed siRNAs may be due to
other factors, including a better recognition by the RISC
machinery, or greater accumulation/duration within cells.
In future studies, we will investigate these possible factors
including the recognition of ANA by the PAZ and PIWI
domains of the RISC complex. Another interesting issue
is that even single modiﬁcations can increase eﬀectiveness.
This might be due to small conformational changes
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Figure 9. Nuclease stability of ANA-modiﬁed siRNAs. Standard MDR1 siRNA or the 2385/2470 ANA-modiﬁed siRNA were exposed to nuclease
activity and the degradation of the siRNAs monitored by agarose gel electophoresis with ethidium bromide staining. Upper panel: exposure to 10%
fetal calf serum for various times. Lower panel: exposure to various doses of micrococcal nuclease.
Nucleic Acids Research, 2007, Vol. 35, No. 4 1073of the duplex introduced by the modiﬁed nucleotide.
The conformational change introduced by a rigid nucleo-
tide is normally transferred to neighboring nucleotides so
that the change is extended over several base pairs.
In summary, the altritol modiﬁcation provides an
RNA-like oligonucleotide that is well suited for siRNA
applications. A number of questions remain as to the
basis of the enhanced eﬀectiveness and persistence of
ANA siRNAs; these will be explored in future work
as will the behavior and utility of ANA siRNAs in the
in vivo setting.
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